Preparation and characterizations of glyceryl oleate ufasomes of terbinafine hydrochloride: a novel approach to trigger Candida albicans fungal infection

Sankha Bhattacharya

Abstract

Background: Worldwide fungal infection cases are increasing by leaps and bounds. The patients who are immunocompromised, i.e., cancer and AIDS, are more susceptible to different types of fungal infections like cutaneous candidiasis and its associate infections. The available treatment for such a disease is creams, gels, etc. However, due to the lack of penetrability and higher systematic absorption, these formulations have reported many side effects. To overcome such challenges, various novel drug delivery systems were introduced. The present research focused on the preparation of glyceryl oleate ufasomes of terbinafine hydrochloride using the film hydration method.

Result: The prepared formulations were characterized for globular size (nm), zeta potential (mV), PDI, morphological characteristics, thermal behavior, in vitro drug release, in vitro antifungal activity, and in vitro skin permeation retention studies. After suitable formulation optimization using thin-film hydration method, 3:7 drug to glyceryl oleate ratio, UF3 formulation was found to produce higher drug entrapment efficacy (52.45 ± 0.56%), stable anionic zeta potential (−33.37 ± 0.231 mV), desired globular size (376.5 ± 0.42 nm), and decent polydispersity index (0.348 ± 0.0345). Diffusion-controlled and zero-order sustained release profile was observed in the optimized UF3 batch. From the 5 days in vitro antifungal activity studies, it confirmed that UF3 ufasomes possessed good applicability in more prolonged therapy.

Conclusion: From the current investigation, it can be concluded that glyceryl oleate ufasomes of terbinafine hydrochloride could be an excellent approach to treat topical fungal infections.

Keywords: Antifungal agent, Cutaneous candidiasis, Glyceryl oleate, In vitro antifungal activity, Terbinafine hydrochloride, Ufasomes

Highlights

- Due to the recent elevation in the number of fungus infections and incapability of current medicaments, it is necessary to prepare a novel drug delivery system to circumvent all challenges.
- In this research work, terbinafine hydrochloride ufasomes were made using glyceryl oleate.
- Prepared ufasomes were characterized for globular size, zeta potential, PDI, morphological characteristics, thermal behavior, in vitro drug release, and in vitro skin permeation retention studies.
- Skin retention of vesicular dispersion was studied in Strat-M® membranes.
- In vitro antifungal activity was performed in Candida albicans-infected male guinea pig.
- UF3 formulation was found to be the optimized formulation with best skin penetration and longer retention potential.
Background

The skin is the outermost protective layer of the human body, which protects internal organs from any kind of external damage [1]. The outer layer of skin is called the epidermis, which is responsible for skin tone. The next layer is the dermis, which is entirely comprised of hair follicles, connective tissues, and sweat glands [2]. The hypodermis or subcutaneous tissues are the deeper layers of the muscles [3]. The bacteria or fungus eventually do some transcutaneous invasion. To avoid such conditions, the outer epidermis acts as a protective barrier [4]. However, the skin permeability could be dogged when the fungus attacks the stratum corneum and ultimately alter the permeability of the skin [5]. The recent research findings are suggesting that more than one billion people of our planet have skin infections. Those patients who are immunocompromised are susceptible for such kinds of skin infections [6]. Mostly, due to the consumption of immunocompromised drugs or diseases like AIDS, leukemia, viral hepatitis, and multiple myeloma, the risk of fungal infections increased in the modern age [7]. Contemporary fungal infections can be virulent and invasive and can spread from subcutaneous to epidermis [8]. To target such fungal infections, it is necessary to have an excellent permeation enhancer. To enhance skin permeation, glyceryl oleate is one of the finest permeation enhancer. Due to the subcutaneous fluidization and polar lipid existing in the various liquid crystal phase, the amphiphilic glyceryl oleate shows higher penetrability into the skin [9]. The different types of essential fatty acids, such as alphanolinolenic acid, linoleic acid, arachidonic acid, and oleic acid, are capable of producing vesicular structure in aqueous conditions [10]. Barreto et al. [11], in their study, prepared garlic liposomes with oleic acid and phosphatidylcholine and checked its antifungal activity in wheat bread [12]. From the thermal gravimetry analysis, it was concluded that oleic acid retards thermal decomposition as compared with phosphatidylcholine liposomes. In another research, Srisuk et al. performed an in vitro permeability study of methotrexate liposomes made up with oleic acid and phosphatidylcholine, which was further compared with liposomes of phosphatidylcholine and cholesterol [13]. The result of this research revealed that liposomes made up of phosphatidylcholine and oleic acid enhanced the skin permeation; hence, maximum methotrexate flux was witnessed in dermis layers of porcine skin. In another research, Sharma et al. has prepared potential fatty acid vesicle comprising with oleic acid for the topical drug delivery of methotrexate [14]. In another research, Salama et al. developed unsaturated fatty acid liposomes or ufasomes using oleic acid [15]. In another study, Sharma and Arora [14] encapsulated methotrexate in oleic acid vesicle to form ufasomes for the treatment of psoriasis; the results were astonishing. The oleic acid methotrexate ufasomes have had maximum entrapment efficacy in rat skin as compared with carbopol-based plain gel [16].

Terbinafine hydrochloride, an allylamine derivative structurally related to naftifine, can block the biosynthesis of ergosterol by suppressing squalene epoxide [17]. This drug can be used to treat different types of skin infections caused by fungus. Terbinafine is highly active against dermatophytes [18]. Eventually, this drug gel and creams are available in the market but how much they are bioavailable or penetrable is still a matter of research [19]. Moreover, some patients often withdraw medication once they are receiving a positive response from it, which ultimately increases the chance of reoccurrence of fungus infections in patients. Moreover, frequent dosing of terbinafine in the skin could increase the likelihood of higher absorption in systematic circulation [20].

As far as fatty acid vesicles are concerned, they can spontaneously grow in alkaline micelles, which are attached to buffer vesicles [21]. These fatty acid vesicles are capable of fusogenic characteristics, which ultimately lead to a reduction of the membrane transition temperature. When fatty vesicles come with the contacts of lipid bilayers of skin, it releases its contents [22]. Therefore, it is established by many types of research that fatty acid vesicles are the most effective carrier to boost skin penetrability through the stratum corneum [23].

In our present study, an attempt was made to prepare effective fatty acid vesicular drug delivery systems or ufasomes of terbinafine hydrochloride using glyceryl oleate for aiming fungus infections which affect the deeper epidermal layer of the skin. This formulation is capable of providing local effects with higher penetrability and reduced dose and toxicity. For preparing glyceryl oleate ufasomes of terbinafine hydrochloride, film hydration methods were used. The different characterization parameters were also addressed in this research.

Methods

Materials

Terbinafine hydrochloride was a gifted sample by Dr. Reddy’s Laboratories (Ameerpet, Hyderabad, Telangana, India), glyceryl tri(oleate-1-13C) was purchased from Sigma-Aldrich (Bangalore, India), Sephadex® G-50 was purchased from Sigma-Aldrich (Bangalore, India), and dialysis tubing cellulose membrane with flat width 10 mm (0.4 in.) was purchased from Sigma-Aldrich (Bangalore, India). The fungal strain Candida albicans (Robin)
Entrapment efficacy was measured after exposing the vesicles in 1 N sodium hydroxide [26]. The release of the terbinafine hydrochloride was measured spectrophotometrically (UV-1280-UV-VIS Spectrophotometer, Shimadzu Life Science, Japan) at 283 nm. The following equation measured the entrapment efficacy:

\[
\text{Entrapment (\%)} = \frac{\text{Entrapped drug}}{\text{Total drug incorporated}} \times 100
\]

Differential scanning electron microscopy
To understand the thermal behavior of drug, drug-loaded vesicles, and blank vesicles, differential scanning electron microscopy was performed (Q-10, TA instrument) [22]. Calibration of heat flow is compulsory before initializing the process. Sample purging was done using inert nitrogen gas at a flow rate of 30 ml/min. The temperature was raised at 20 °C/min increments.

In vitro drug release studies
The dialysis tubing cellulose membrane with flat width 10 mm (0.4 in) was used for the in vitro dialysis of glyceryl olate ufasomes. For proper execution of this study, 5 mL glyceryl olate ufasomes were taken into dialysis tubing and both ends were tied using nylon thread and dispersed into a conical flask comprising of 50 mL pH 5.5 phosphate buffer solution containing 0.01% sodium lauryl sulfate. The conical flask was further incubated into an incubated shaker for 15 min in 37 °C at 60 rpm. Also, a 5-mL sample was withdrawn from the bottle, and 5 mL of fresh buffer was added into the conical flask. The withdrawn sample was filtered and determined spectrophotometrically at 283 nm.

Berkhout (ATCC® 10231™) was a gift sample from RK University (Rajkot, India), synthetics non-human skin called Strat-M* membrane arranged from Millipore (Canada), and the rest of the samples were analytical grades and purchased from Rankem Laboratories (Gurugram, Haryana, India).

Preparation of terbinafine hydrochloride ufasomes
By using a thin-film hydration method, the terbinafine hydrochloride ufasomes were prepared in a round-bottom flask. After slide modification of the Sharma et al. [14] procedure, new preparation steps were incorporated [24]. Initially, terbinafine hydrochloride and glyceryl olate were dissolved in dichloromethane and kept in a round-bottomed flask for vacuum drying using a rotary evaporator (IKA-RV 3 V-C Digital Rotatory Evaporator, Germany). The assembly was set for 50 rpm at 45 °C. After overnight vacuum drying, a dried thin film formed, indicating complete removal of residual solvent. The thin film was further hydrated for 12 h with freshly prepared pH 5.5 phosphate buffer solution. The mixture was further sonicated in 1.5 L Athena Ultrasonic Bath Sonicator for 15 min to form uniform vesicular dispersion. Also, optimization is performed by changing the ratios of terbinafine hydrochloride and glyceryl olate. The manual optimization procedure followed, where different ratios of terbinafine hydrochloride and glyceryl olate were screen for the best optimization batch. A total of five (UF1–UF5) formulations batches was prepared, and subsequently, the best formulation batch has been selected after suitable statistical screening (p < 0.05). The unentrapped drug was separated from the formulations using OMNISEC Gel permeation Chromatography (Malvern Panalytical, UK), considering borate buffer as eluent.

Vesicular size, zeta potential, and morphological characterization of glyceryl olate vesicles
Delsa Nano C Particle Size and Zeta Potential Analyzer (Beckman Coulter, USA) was used for accurate vesicular size and zeta potential measurement [25]. For measuring the internal morphology and surface characterization of the vesicles, transmission electron microscopy (JEOL Transmission Electron Microscopes, USA) and mitotic compound microscope (BA210 LE, Germany) were used.

In vitro antifungal activity of glyceryl olate ufasomes
The cup plate method was incorporated to estimate the antifungal activity of glyceryl olate ufasomes. Initially, Candida albicans was first grown overnight and inoculated into Sabouraud dextrose agar (SDA) media plates. Using cork borer, 10-mm diameter, three wells were introduced after solidification of Candida albicans in media plates. In the first good glyceryl olate, 30% w/w ufasomes was placed as a test group; in the second well, plain 2% w/w terbinafine hydrochloride was placed in third pH 5.5 phosphate buffer solution was placed, which is considered a controlled group. The plates were incubated for 48 h at 37 °C. At different time intervals, the zone of inhibition was measured for the control, plan drug, and test sample.

In vitro skin permeation study for glyceryl olate ufasomes
Using Franz diffusion cell (Dolphin Pharmacy Instruments Private Limited, India) in vitro skin permeation study for glyceryl olate ufasomes (sample A), marketed gel (B-Fine, Cian Healthcare Limited, Mumbai, India) and plain drug of terbinafine hydrochloride (gift sample, Dr. Reddy’s Laboratories) were carried out. The diffusion area for the Franz diffusion cell was 4.5 cm², and the 60-ml volume was kept inside. The penetration study was done using a synthetic non-animal-based model called
47 mm 60/pk Strat-M® membrane [27] (Millipore, Canada), which is specifically designed to mimic human skin. The most significant advantages of this synthetic skin are no need for an animal model, deficient human to animal skin variability alternative (CV = 8%), almost around 1.38 correlation to human skin, and longer self-life with no specific storage requirement. In the experimental procedure, the disk-shaped Strat-M® membrane was plucked using forceps and socked into a Petri dish, continuing 10 mL of saline water.

Further, the Strat-M® membrane was placed into the donor compartment of the Franz diffusion cell using forceps and maintain temperature around 35–37 °C. Thirty percent w/w optimized glyceryl oleate ufasomes, 1% w/w B-Fine Marketed gel (2.91 mg equivalent of terbinafine hydrochloride), and 2.91 mg of terbinafine hydrochloride were placed in the donor compartment of three different Franz diffusion cell. Nearly 0.5 mL of samples were withdrawn from the acceptor compartments for various time alternatives within 24 h using digital micropipettes (Thermo FisherScientific India Private Limited, Mumbai, India). The same amount of buffer solutions was added to the maintained sink condition in the acceptor compartment. The filtered samples were analyzed using UV-1280-UV-VIS Spectrophotometer (Shimadzu Life Science, Japan) at 283 nm.

**Skin retention of vesicular dispersion**

After performing in vitro skin permeation studies in three Strat-M® membranes [28], the utilized membranes were carefully removed from the Franz diffusion cell and subsequently chopped into small pieces. Now, 50 mL of pH 5.5 methanolic phosphate buffer (6:4) was added into the cut pieces and placed in shakers incubators with Vortexes Stirrer (Athena Technology, Mumbai, India) for 1 h at 37 °C. This procedure completely extracts drug from the embedded Strat-M® membrane. After extraction, the resultant solutions were filtered using a compact cooling centrifuge (Remi Elektrotechnik Limited, Mumbai, India) and using UV-1280-UV-VIS Spectrophotometer at 283 nm the embedded amount of drug estimated.

The skin retention was calculated using the following formula:

\[
\text{Skin retention (\%)} = \frac{\text{amount of drug embedded in Strat-M® Membranes}}{\text{Total drug incorporated}} \times 100
\]

**In vivo studies**

While performing animal studies, the Committee for Control and Supervision of Experiments on Animals (CPCSEA) guidelines issued by the Government of India followed. The animal ethical committee approved all the study protocol of ISF College of Pharmacy, Moga, Punjab, India.

**In vivo antifungal activity of gel**

In developing a model of immunocompromised animals, 5 mg/kg/bodyweight of Cyclosporine, a calcineurin Inhibitor, the injection was administered subcutaneously in 450–500 g weighted male Guinea pig. Cyclosporine was applied five times, i.e., 3 days before the injection of fungal suspension and 2 days after the inoculation of the suspension.

**Preparation of Candida albicans inoculums**

*Candida albicans* (Robin) Berkhout (ATCC® 10231”) was utilized to inoculate fungal infections in the Guinea pig. Initially, it is necessary to prepare a culture strain. For this purpose, sabouraud dextrose agar solution was used. The *Candida albicans* were inoculated in it for 48 h for 37 °C. The expressed cells were collected and resuspended in sterile saline. It was making sure that the final concentration in the sterile saline must be 10^7 colony-forming unit/mL (cfu/mL)

**Initiation of fungal infection in the skin**

Before shaving the animals back, it is necessary to anaesthesia the animal using 5–10 mg/k IM Ketamine. The back was shaved using NOVA Electric Trimmer Clipper. The total surface area trimmed was 3.0 cm^2. Each animal body back surface area was inoculated with 10^7 cfu/mL of *Candida albicans* dispersion using a sterile cotton swab (socked in 70% v/v ethanol). The swab was rubbed on the surface of anesthetized animals unless and until no fluid certain in the animal body surface. Further, animals were caged separately. Animals were observed from time to time, and the sign of intense erythema was investigated into the site on the animal body.

**Treatment of Candida albicans-induced infection**

Once the symptoms of infections were palpable, the treatment would begin. The animals were devised into four groups. Each group contains four animals. The first group was treated with marketed B-Fine gel, equivalent to 5.8 mg of terbinafine hydrochloride (sample A); the second group was treated with terbinafine hydrochloride-loaded glyceryl oleate ufasomes, equivalent to 5.8 mg of terbinafine hydrochloride (sample B); the third group was treated with 5.5 mg of terbinafine hydrochloride, which was sprinkled on the surface of exposed skin (sample C); and finally the fourth group was exposed with the pH 5.5 phosphate buffer solution, which is considered a controlled group (sample D). Before applying samples from A to D in animal skin, one animal from each group was sacrificed to check the initial colony count (day 0), as prescribed in Aggarwal and Goindi [29]. For the 3 alternative
days, animals were ingested with treatment once in a day. For the measurement of the colony count, 24 h after the last treatment, each animal from each group was sacrificed (day 1), subsequently after 72 h (day 3) and 120 h (day 5); the same procedure was followed for each and every group. Further, the treatment skin was separated from the animal body and carefully soaked in saline solution and homogenized. An aliquoted portion of homogenate was placed in sabouraud dextrose agar (SDS) plates for 48 h at 37 °C, and colony-forming unit (cfu) value was recorded using digital colony counter (J. S. Enterprises, New Delhi, India).

Statistical analysis
Using analysis of variance (ANOVA), the treatment group was analyzed with a controlled group. The multiple comparison test of ANOVA was performed in GraphPad Prism v.7.0 (San Diego, Canada). All the results were expressed in mean ± SD. The p value < 0.05 was considered significant.

Result
Morphological characterization of glyceryl oleate ufasomes of terbinafine hydrochloride
The shape and morphology of ufasomes were determined by using motic compound microscope (BA210 LE, Germany) and transmission electron microscopy (JEOL Transmission Electron Microscopes, USA). The optimized ufasomes were stained using sulforhodamine B solution (sulforhodamine B solution previously prepared using 0.5% solutions of acetic acid and water) for the motic microscopic studies. The motic image of glyceryl oleate ufasomes of terbinafine hydrochloride was shown in Fig. 1a, and the TEM image of the same as shown in Fig. 1b. The two images clearly indicating prepared ufasomes were spherical in shape and size is below 500 nm.

Globular size, percentage drug entrapment efficacy, and colloidal nature of ufasomes
Prepared ufasomes of terbinafine hydrochloride characterized by zeta potential, drug entrapment efficacy, polydispersity index, and particle size. Table 1 represents the process of optimization. In the process of optimization, it was observed that UF3 formulation was found to be statistically significant (The p value < 0.05) as compared to other formulations. From the Table 1, it is signifying that drug-glyceryl oleate 3:7 molar ratio of UF3 formulation possessed with optimum globular size 376.5 ± 0.42 nm (Fig. 2a) with more stable anionic zeta potential –33.37 ± 0.231 mV (Fig. 2b). Another interesting fact that is observed is the increased molar ratio of glyceryl oleate after UF3 formulation decreases the entrapment of the ufasomes. It is due to the increase in the concentration of drug in the bilayer of ufasomes. Moreover, the higher anionic zeta potential of UF4 and UF5 also would be the reason for instability in these formulations. Further addition of drugs could lead to instability within the ufasomes molecule, and subsequently leakage would be palpable. Since UF3 was showing excellent colloidal stability and least particle size among all the beaches, hence it could be anticipating that UF3 would have good skin penetration behavior.

Differential scanning calorimetry (DSC)
Thermal behavior and drug lipid conjugation can be identified using DSC analysis. The thermogram of the drug, blank ufasomes, and drug-loaded ufasomes was shown in Fig. 3. A sharp endothermic peak of terbinafine hydrochloride at 178.43 °C indicating the melting of the drug. Most importantly, no characteristic drug peak was found in drug-loaded ufasomes of glyceryl oleate, meaning the drug was possibly encapsulated or entrapped in glyceryl oleate vesicles, which is justifying the higher entrapment efficacy of UF3-optimized formulation. It was

![Fig. 1 a](image1) The yellow circles indicating the formation of ufasomes in the slide. b Transmission electron microscopy (TEM) image of glyceryl oleate ufasomes of terbinafine hydrochloride at 80 kV and × 50,000
also observed that melting enthalpy and peak intensity were changed marginally for UF1, UF2, UF4, and UF5 formulations; this could be due to the lower entrapment of the drug molecule within the formulation. However, no such shift was observed when optimized UF3 was compared with blank glyceryl oleate ufasomes, indicating highly stable formulation.

**In vitro drug release study**

Dialysis tubing cellulose membrane with flat width 10 mm (0.4 in.) used to carry out in vitro drug release study. The in vitro drug release profiling from UF1 to UF5 is mentioned in Fig. 4. The drug release profiles from different formulation batches, suggesting that a minimum 38.48% cumulative drug release was witnessed in UF2 formulation. Where else, a maximum 55.48% cumulative drug release was seen in UF3-optimized formulation after 30 h. The drug release kinetics is depicted in Table 2. Almost all the formulation was showing zero-order release kinetics; since, the $R^2$ value in the zero-order model was showing a maximum. The Korsmeyer-Pappas release exponential ($n$) was leading the amount from 0.356 to 0.432, which indicates diffusional release kinetics in UF1 to UF2 formulations. However, UF3 formulations have shown entirely zero-order kinetics ($R^2 = 0.9926$). Nevertheless, from Fig. 4, it is indicating that during 15–25 h of drug release, the formulations (UF1–UF5) are showing maximum zero-order kinetics.

**In vitro antifungal activity of applied ufasomes in animal skin**

In Fig. 5, the antifungal activity of UF1 to UF5 was reported against *Candida albicans*. The zone of inhibition is not witnessed in the controlled group. However, it was noticed that a sharp increase in the zone of inhibition seen in plain terbinafine hydrochloride up to the 36th hours as compared to the ufasome formulations (UF1–UF5). But from the 48th hours onwards, the zone of inhibition decreased in plain drug; however, for almost all the ufasome formulations (UF1–UF5) a sharp increase in zone of inhibition perceived from the 48th hour. This is due to the diffusion-controlled release of the drug from the ufasomes surface after the 48th hour. Once again, UF3 was showing the highest zone of inhibition (21.2 mm) claimed to be an optimized formulation among all the formulations.

| Table 1 Optimization of ufasomes of terbinafine hydrochloride (where value represented in mean ± SD [n = 3]) |
|---|
| **Formulation code** | **Terbinafine hydrochloride to glyceryl oleate** | **Globular size (nm)** | **Zeta potential (mV)** | **PDI** | **Drug entrapment (%)** |
| UF1 | 5:5 | 610.1 ± 0.37 | −26.58 ± 0.32 | 0.527 ± 0.043 | 45.29 ± 0.27 |
| UF2 | 4:6 | 542.3 ± 0.22 | −28.52 ± 0.21 | 0.403 ± 0.037 | 48.28 ± 0.18 |
| UF3 | 3:7 | 376.5 ± 0.42 | −33.37 ± 0.231 | 0.348 ± 0.0345 | 52.45 ± 0.56 |
| UF4 | 2:8 | 423.6 ± 0.42 | −34.27 ± 0.11 | 0.427 ± 0.0378 | 42.56 ± 0.35 |
| UF5 | 1:9 | 510.4 ± 0.29 | −38.21 ± 0.45 | 0.528 ± 0.053 | 38.67 ± 0.05 |

Fig. 2 a Globular size of optimized ufasomes (UF3). b Zeta potential of optimized ufasomes (UF3).
In vitro skin permeation studies were exercised on a non-animal-based model called 47 mm 60/pk Strat-M® membrane (Millipore, Canada), which was specially designed to mimic human skin. The in vitro skin permeation study performed in Franz diffusion cell (Dolphin Pharmaceutical Instruments Private Limited, India). From Fig. 6 it is clear that UF3 formulation had a less penetration in Strat-M® membrane compared to B-Fine-marketed formulation. The drug permeation of UF3 is less, i.e., 15.78 ± 1.21% at the 24th hour; that means it has more retention index within the skin. The drug permeation of UF3 was low because the presence of glyceryl oleate in ufasomes increases the drug retention within the pores of Strat-M® membrane. The drug permeation from the B-Fine marketed cream is more because the formulation did not have any carrier system to hold the drug within.

Fig. 3 DSC thermograph of terbinafine hydrochloride showing a sharp endothermic peak at 178.43 °C (reported melting point > 202 °C), indicating melting of the drug, in case of blank glyceryl oleate ufasomes, apart from the sharp melting point at 51.45 °C; a less intense peak was observed in 304.43 °C; however, no characteristic drug peak was observed in drug-loaded ufasomes of glyceryl oleate.

Fig. 4 In vitro drug release profile of different batches of ufasomes (UF1–UF5). The values were articulated as mean ± SD (n = 3).
Skin retention of UF3 formulation and B-fine marketed cream
From the previous in vitro skin permeation experiment, it was confirmed that optimized glyceryl oleate ufasomes of terbinafine hydrochloride (UF3) possessed a drug reservoir effect in Strat-M® membrane. The percentage of terbinafine hydrochloride deposition was compared with B-Fine marketed formulation. The amount of drug retained in UF3 formulation in the 24th hour was 62.56 ± 0.64%, whereas B-Fine marketed gel shows 14.52 ± 1.43% in the same hour. Figure 7 showing skin retention studies.

In vitro antifungal activity studies against Candida albicans
As described earlier, the in vitro antifungal activity of terbinafine hydrochloride, UF3, and B-Fine marketed formulation was determined by persuading Candida albicans based on infection in animal skin. From Fig. 8, it was indicated that UF3 has prominent antifungal activity against Candida albicans as compare to B-Fine marketed formulation and terbinafine hydrochloride plain drug. At initial day 0, almost all the groups were showing the same colony count (6.25 log cfu/mL), which indirectly indicates that Candida albicans initialized fungus infections in the dermal layer of animal skin. Once the fungal progression was confirmed in the skin, the treatment process was ignited for successive days. On the 1st day, the controlled group was showing marginal growth in colony count (6.88 log cfu/mL), which is due to the propagation of Candida albicans in pH 5.5 phosphate buffer solution. On the other hand, due to the immediate release of terbinafine hydrochloride from the skin surface, on the first day, the plain drug (4.25 log cfu/mL) and B-Fine marketed gel (3.58 log cfu/mL) were showing good activity against Candida albicans. In the case of UF3 formulation, colony count was showing higher as compare to B-Fine gel in the 1st day (4.05 log cfu/mL). This phenomenon could be due to the lower amount of drug release from vesicular dispersion of UF3. The presence of glyceryl oleate in ufasomes retards the drug release. Further, after 72 h or the 3rd day, the colony count was started increasing drastically in plain drug (5.45–6.03 log cfu/mL), and B-Fine marketed-induced treatment (3.98–4.84 log cfu/mL), producing fewer significant statistics as

| Ufasome formulation code | Higuchi ($R^2$) | Zero-order ($R^2$) | First-order ($R^2$) | Korsmeyer-Pappas release exponential (n) |
|--------------------------|----------------|------------------|------------------|----------------------------------------|
| UF1                      | 0.293          | 0.9638           | 0.943            | 0.356                                  |
| UF2                      | 0.305          | 0.9561           | 0.9728           | 0.363                                  |
| UF3                      | 0.356          | 0.9926           | 0.9864           | 0.432                                  |
| UF4                      | 0.327          | 0.9835           | 0.9729           | 0.398                                  |
| UF5                      | 0.305          | 0.9802           | 0.9629           | 0.374                                  |

Fig. 5 In vitro antifungal activity of UF1–UF5 formulation. As expected, UF3 was showing excellent against Candida albicans. Values were expressed as mean ± SD (n = 3)
compared to the controlled group. The multiple comparison two-way ANOVA and Tukey test statistics were performed by GraphPad Prism 8.0 software. Super increase in colony count in plain drug and B-Fine marketed gel was due to the excessive release of the drug after the 1st day. Hence, no drug was available for further action ($p < 0.05$).

In 5th day, there is significant declined ($p < 0.05$) in colony count (1.12 log cfu/mL) in UF3-treated skin, indicating reserve ware effect of glyceryl oleate ufasomes, and therefore, therapeutic efficacy of UF3 was found to be better as compared to plain drug and B-Fine marketed drug.

**Discussion**

Ufasomes are unsaturated fatty acid suspensions that have lipid bilayer and a fatty acid composite [30]. So far, very few researches have been carried out in this direction. Many lipid-based formulations could be developed, i.e., liposomes, exosome, noisome, and ethosome for such studies [31]. However, ufasome formulations have many advantages than the other lipid-based formulations, i.e., ufasomes are highly penetrable as compared to similar lipid-based formulations; furthermore, as far as the entrapment efficacy is concerned, ufasomes depicts higher entrapment percentage as compared with analogous lipid-based formulations [32]. This is because the drug itself configured with lipid to form stable fatty acid vesicles. But this manuscript is entitled to provide ufasome-based drug delivery of terbinafine hydrochloride (2% w/w) for the treatment of Candida albicans fungal infection [33]. By utilizing the thin-film hydration method, terbinafine hydrochloride ufasomes are prepared in a round bottom flask. During the preparation process, it observed that a 3:7 ratio of drug and glyceryl oleate produces the best qualitative ufasomes. The cationic nature of optimized ufasomes (UF3) witnessed from the optimized zeta potential, i.e., $33.37 \pm 0.231$ mV, which indicates the prepared ufasomes are having excellent physical stability with little agglomeration. From the DSC analysis, it confirmed that drugs started melting at 178.43 °C. However, no such peak persisted in prepared ufasomes while analyzing the DSC graph, which indicates glyceryl oleate vesicles encapsulated drugs consistently. It was also a parameter that shows physical stability and possible higher entrapment efficacy of the prepared ufasomes. From the in vitro drug release studies, it was confirmed that a maximum 55.48% cumulative drug release was seen in UF3-optimized formulation after 30 h with zero-order kinetics. From the in vitro antifungal activity of applied ufasomes in animal skin, it was confirmed that UF3 was showing the highest zone of inhibition (21.2 mm) claimed to be an optimized formulation among all the formulations. Nevertheless, from the in vitro antifungal activity studies, it confirmed that almost all the formulations have a higher zone of inhibitions compared to the plain drug, which indicates a robust antifungal activity of the prepared ufasomes. The unique feature of this study was utilization of Strat-M® membrane (Millipore, Canada) for in vitro skin permeability studies. Surprisingly, drug retention in Strat-M® membrane was found to be higher as compared with the B-Fine marketed gel, which indicates prepared ufasomes had less permeation within the skin and have an
excellent qualitative carrier system within. From the diffusion studies, the zero-order drug release nature of the formulations was identified, which means formulation could retain in the skin and release drug sustainability. From this study, one more thing is more prominent, i.e., the presence of glyceryl oleate in ufasomes produces reservoir effects. Finally, from the in vitro antifungal activity studies against Candida albicans, it was confirmed that optimized formulation (UF3) provides higher antifungal activity against the marketed drug. Therefore, UF3 formulations were found to be the best candidate to trigger the antifungal effect against Candida albicans-induced associated fungal infections.

**Conclusion**

The effect of size in drug delivery, effective drug to lipid ratio, entrapment efficacy was studied in current research. For the in vitro skin permeation and in vitro antifungal activity studies, plain drug and vesicular dispersion of drug was compared with the marketed formulation. After the induction of cutaneous candidiasis in rats, the research revealed that ufasomes of glyceryl oleate produces good antifungal activity after 5 days of study. Therefore, ufasomes were found to be more effective as compared with the marketed product. Moreover, the FU3 formulation was found to be the optimized formulation. Due to the presence of glyceryl oleate in ufasomes, it has become an excellent drug delivery carrier for any antifungal drugs. Glyceryl oleate could quickly form droplets in the skin to easily be distributed and penetrated within the skin. However, more research needs to be warranted to prepare cationic-based ufasomes for better stability. From this research, it concluded that UF3 could be effective against Candida albicans-induced associated fungal infections.

**Acknowledgements**

The author is like to acknowledge the help and motivation of Dr. R.S. Gaud, Director, SVKM’s NMIMS Deemed-to-be University, Shirpur Campus, and Dr. Ambikanandan Misra, Director Pharmaceutical Research, Shobhaben Pratapbhai School of Pharmacy & Technology Management, SVKM’s NMIMS Deemed-to-be University, for providing excellent research facilities and profound motivation while perusing this project.

**Author’s contributions**

Conceptualization, supervision, validation, visualization, writing—original draft, and writing—review and editing. The authors read and approved the final manuscript.

**Funding**

No funding is required. Only internal institutional funding utilized.

**Availability of data and materials**

Will be made available on request.

**Ethics approval and consent to participate**

All the animal experiments were performed only after the Committee for the Purpose of Control And Supervision of Experiments on Animals (CPCSEA) prior approval (IFSCP/AEC/CPCSEA/Meeting No.26/2020/Protocol No. 452)

**Consent for publication**

Not applicable
Competing interests
The author declares that the author has no competing interests.

Received: 24 July 2020 Accepted: 18 November 2020
Published online: 07 January 2021

References
1. Hardy JD, Muschenheim C (1934) The radiation of heat from the human body. IV. The emission, reflection, and transmission of infra-red radiation by the human skin. J Clin Invest 13(5):817–831
2. McLafferty E, Hendry C, Farley A (2012) The integumentary system: anatomy, physiology and function of skin. Nurs Stand (through 2013) 27(3):35
3. Lancenotte L, Stecco C, Macchi V, Porzionato A, Stecco A, De Caro R (2011) Layers of the abdominal wall: anatomical investigation of subcutaneous tissue and superficial fascia. Surg Radiol Anat 33(10):835–842
4. Elias PM (2007) The skin barrier as an innate immune element. In: Seminars in immunopathology. Springer. Vol. 29. No. 1
5. Lefebvre CL (1934) Penetration and development of the fungus, Beauveria bassiana, in the tissues of the corn borer. Ann Bot 48(190):441–452
6. Brown GJ, Denning DW, Gow NA, Levitz SM, Netea MG, White TC (2012) Beauveria bassiana in immunopathology. Springer. Vol. 29. No. 1
7. Al-Jabri AA, Balkhair AA (2007) Essential immune responses to hepatitis B virus infection. Hepat B Res Adv 253
8. Garber G (2001) An overview of fungal infections. Drugs 61(1):1–12
9. Sharma VK, Sarwa KK, Mazumder B (2014) Fluidity enhancement: a critical factor for performance of liposomal transdermal drug delivery system. J Liposome Res 24(2):83–89
10. Liu JJ, Green P, Mann JI, Rapoport SL, Sublette ME (2015) Pathways of polynaturated fatty acid utilization: implications for brain function in neuropsychiatric health and disease. Brain Res 1597:220–246
11. Pinilla CMB, Thyss RCS, Brandelli A (2019) Antifungal properties of phosphatidylycholnole-oleic acid liposomes encapsulating garlic against environmental fungal in wheat bread. Int J Food Microbiol. 293:72–78. https://doi.org/10.1016/j.ijfoodmicro.2019.01.006 Epub 2019 Jan 12. PMID: 30660071
12. Lopes NA, Pinilla CMB, Brandelli A (2017) Pectin and polygalacturonic acid-coated liposomes as novel delivery system for nisin: preparation, characterization and release behavior. Food Hydrocoll 70:1–7
13. Srivak P, Thongnopnua P, Raktanochal U, Kanokpanont S (2012) Physicochemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment. Int J Pharm 427(2):426–434
14. Sharma, A., & Arora, S. (2012). Formulation and in vitro evaluation of ufasomes for dermal administration of methotrexate. ISRN pharmaceutics. 2012
15. Salama AH, Aburahma MH (2016) Ufasomes nano-vesicles-based lyophilized pharmaceutical carrier for dermal and transdermal drug delivery: formulation development, stability issues, basic considerations and applications. J Control Release 270:203–225
16. Nair AB, Kim HD, Chakraborty B, Singh J, Zaman M, Gupta A, Murthy SN (2009). Ungual and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis. J Pharm Sci 98(11):4130–4140
17. Stano P, Lušti PL (2010) Achievements and open questions in the self-reproduction of vesicles and synthetic minimal cells. Chem Commun 46(21): 3559–3563
18. El Magnaby GM, Barry BW, Williams AC (2008) Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci 34(5-6):203–222
19. Rai VK, Mishra N, Yadav KS, Yadav NP (2018) Nanomulsion as pharmaceutical carrier for dermal and transdermal drug delivery: formulation development, stability issues, basic considerations and applications. J Control Release 270:203–225
20. Nair AB, Kim HD, Chakraborty B, Singh J, Zaman M, Gupta A, Murthy SN (2009). Ungual and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis. J Pharm Sci 98(11):4130–4140
21. Stano P, Lušti PL (2010) Achievements and open questions in the self-reproduction of vesicles and synthetic minimal cells. Chem Commun 46(21): 3559–3563
22. El Magnaby GM, Barry BW, Williams AC (2008) Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci 34(5-6):203–222
23. Cevc G, Vierl U, Magzareanu S (2008) Functional characterisation of novel analgesic product based on self-regulating drug carriers. Int J Pharm 360(1-2):18–28
24. Verma S, Bhardwaj A, Vij M, Rajpal P, Goutam N, Kumar L (2014) Oleic acid vesicles: a new approach for topical delivery of antifungal agent. Artif Cells Nanomedicine Biotechnol 42(2):95–101
25. Bose S, Michniak-Kohn B (2013) Preparation and characterization of lipid based nanosystems for topical delivery of quercetin. Eur J Pharm Sci 48(3): 442–452
26. Gupta PN, Mishra V, Rawat A, Dubey P, Mahor S, Jain S, Vyas SP (2005) Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study. Int J Pharm 293(1-2):73–82
27. Haq A, Goodyear B, Ameen D, Joshi V, Michniak-Kohn B (2018) Strat-M® synthetic membrane: permeability comparison to human cadaver skin. Int J Pharm 547(1-2):432–437
28. Uchida T, Kadhum WR, Kanai S, Todo H, Oshizaka T, Sugibayashi K (2015) Prediction of skin permeation by chemical compounds using the artificial membrane, Strat-M®. Eur J Pharm Sci. 67:113–118
29. Agarwal N, Goindi S (2012) Preparation and evaluation of antifungal efficacy of griseofulvin loaded deformable membrane vesicles in optimized guinea pig model of Microsporum canis—Dermatophytosis. Int J Pharm 437(1-2):277–287
30. Naik PV, Dvst SG (2008) Ufasomes as plausible carriers for horizontal gene transfer. J Dispers Sci Technol 29(6):804–808
31. Soltani F, Parhiz H, Mokhtarzadeh A, Ramezani M (2015) Synthetic and biological vesicular nano-carriers designed for gene delivery. Curr Pharm Des 21(42):6214–6235
32. Gupta R, Agrawal A, Meraj Anjum M, Dwivedi H, M Kymonil K, A Saraf S (2014) Lipid nanoformulations for oral delivery of bioactives: an overview. Curr Drug Ther 9(1):35–46
33. Martin MH (1999) The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review. J Antimicrob Chemother 44(4):429–437

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com